Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the determination of sanfetrinem in human plasma.
A rapid, selective and accurate high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of sanfetrinem in human plasma has been developed and validated. The performance of manual and automated sample preparation was assessed; 50 microl of plasma sample was deproteinized with acetonitrile, followed by dilution with water and injection onto the LC system. Chromatographic separation was achieved on a Phenomenex Luna C18(2), 50x2.0 (5 microm) column with a mobile phase consisting of water-acetonitrile with 0.1% formic acid followed by detection with a Perkin-Elmer API3000 mass spectrometer in multiple reaction monitoring mode. The lower limit of quantification was improved by five times compared to the UV method previously reported. A range of concentration from 10 ng/ml to 5 microg/ml was covered. The method was applied to the quantification of sanfetrinem in human plasma samples from healthy volunteers participating in a clinical study.
De Nardi
C
C
Bioanalytical and Drug Metabolism Department, GlaxoWellcome SpA., Medicines Research Center, Verona, Italy. cdn68303@glaxowellcome.co.uk
Braggio
S
S
Ferrari
L
L
Fontana
S
S
D000900:Anti-Bacterial Agents / Q000097:blood*; D000890:Anti-Infective Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D007769:Lactams; D013058:Mass Spectrometry / Q000379:methods*; D012680:Sensitivity and Specificity
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007769:Lactams; C104757:sanfetrinem